Review decision – July 2019
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA408; Pegaspargase for treating acute lymphoblastic leukaemia.
No new cost or clinical effectiveness data which would lead to a change in the recommendations for technology appraisal 408 have been identified.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently, TA408 will move to the ‘static list’ of technology appraisals.
This page was last updated: